

Table S1: HLA risk alleles associations with DHRs

Drug	HLA Risk Allele	Reaction	Ethnic Population	PPV (NPV)*	Key Ref.
Antibiotics					
Amoxicillin-clavulanate	DRB1*15:01	DILI	Caucasian		(1)
	DQB1*0602				
	A*02:01				
Benznidazole	A*11:01	MPE, DRESS	Bolivian	100 (70)	(2)
	A*29:02			100 (70)	
	A*68			48 (84)	
Dapsone	B*13:01	DRESS	Chinese	7.8 (99.8)	(3)
		DRESS, SJS/TEN	Thai		(4)
		DRESS	Taiwanese Malaysian		(5)
Flucloxacillin	B*53:01	DILI	European		(6)
	B*57:01		Caucasian	0.12 (99.99)	(7)
Minocycline	B*35:02	DILI	Caucasian		(8)
Sulfamethoxazole	A*29	SJS/TEN	Caucasian		(9)
	A*30	FDE	Turkish		(10)
	A*30-B*13-C*06				
	A*11:01	SJS/DRESS	Japanese		(11)
	B*13:01	SCAR	Asian	4.05 (99.92)	(12)
		DRESS		3.64 (99.92)	
	B*14:01	DILI	European American		(13)
	B*35:01		African American		(13)
	B*44 (B12 serotype)	SJS/TEN	Caucasian		(9)
	B*38		Caucasian		(14)
DR*07	Caucasian			(9)	
Terbinafine	A*33:01	DILI	European		(15)
Vancomycin	A*32:01	DRESS	Caucasian		(16)
Anticonvulsants					
Carbamazepine	A*02:01	MPE	Han Chinese		(17)
	A*24:02	SJS/TEN	Han Chinese		(18)
	A*31	DRESS,	Japanese		(19)

		SJS/TEN, MPE			
	A*31:01	DRESS	Caucasian	0.77 (99.98)	(20)
			Han Chinese	0.67 (99.97)	(20)
		SJS/TEN	Caucasian		(21)
			Han Chinese		(20)
		DRESS, SJS/TEN	Korean		(22)
	SCAR, DILI	Caucasian		(23)	
	B*15:02	SJS/TEN	Han Chinese	2.24 (99.94)	(20, 24)
			Indian		(25)
			Korean		(24)
			Malaysian		(24)
			Thai		(24, 26)
	B*15:11	SJS/TEN	Taiwanese	93.6 (100)	(27)
			Han Chinese		(18)
	B*15:21	SJS/TEN	Asian	43.8 (95.1)	(28)
			Thai		(26)
	B*51:01	SJS/TEN	Filipino	1.03 (87.5)	(29)
	B*57:01	DRESS, MPE	Han Chinese		(28)
	B*58:01	SJS/TEN	Caucasian		(30)
	B*58:01	DRESS, MPE	Asian	90.4 (37)	(26, 28)
	DRB1*14:05	MPE	Han Chinese		(17)
Lamotrigine	A*02:07	MPE, DRESS, SJS/TEN	Thai		(31)
	A*24:02, C*01:02	MPE	Korean		(32)
	A*30:01		Han Chinese		(17)
	B*13:02		Thai		(31)
	A*33:03				
	B*44:03				
	A*31:01	DRESS, SJS/TEN	Korean		(33)
	A*68:01	DRESS, SJS/TEN	Caucasian		(34)
	B*15:02	SJS/TEN	Han Chinese		(35)
		DRESS, SJS/TEN, MPE	Thai		(31)
		SJS/TEN	Iranian	78.57 (56.41)	(36)
	B*38	SJS/TEN	Caucasian		(14)
	B*58:01	DRESS, SJS/TEN	Caucasian		(34)
C*07:18					

	DQB1*06				
	DRB1*13				
Oxcarbazepine	A*03:01	MPE	Uighur Chinese		(37)
	B*07:02				
	B*15:02	MPE, SJS/TEN	Han Chinese		(38)
	B*38:02	MPE			(39)
Phenobarbital	B*51:01	SJS/TEN	Japanese		(40)
Phenytoin	B*13:01	SJS/TEN	East Asian		(41)
	B*15:02	SJS/TEN	East Asian		(41)
			Han Chinese		(35)
			Malaysian		(42)
			Thai	33 (100)	(43)
	B*15:13	DRESS, SJS/TEN	Malaysian		(42)
	B*56:02	SJS/TEN	Thai		(44)
		DRESS	Australian Aboriginal		(45)
		Cw*08:01 DRB1*16:02	SJS/TEN	Han Chinese	
Zonisamide	A*02:07	SJS/TEN	Japanese		(40)
Antiretrovirals					
Abacavir	B*57:01	HSS	African	50 (100)	(47)
			Caucasian	50 (100)	(48, 49)
			Hispanic	96 (60)	(50)
Nevirapine	Cw4	DRESS	Han Chinese		(51)
	C*04:01	SJS/TEN	Malawian	2.6 (99.2)	(52, 53)
	C*08	DRESS	Japanese		(54)
	C*08:02, B*14:02	DRESS	Caucasian (Sardinian)		(55)
	B*35:05	Skin Rash	Thai		(56)
	DRB1*01:01	DRESS	Caucasian		(57)
Raltegravir	B*53:01	DRESS	African		(58)
Other drugs					
Acetazolamide	B*59	SJS/TEN	Korean		(59)
Asparaginase	DQB1*02:0 2- DRB1*07:01 - DQA1*02:0 1		European		(60)
	DRB1*02:01	Anaphylaxis		Caucasian	
	DRB1*07:01				(61)
Allopurinol	B*58:01	DRESS,	Caucasian		(62)

		SJS/TEN			
		DRESS	Caucasian (Portuguese)		(63)
		DRESS, SJS/TEN	Han Chinese	3 (100)	(64)
		DRESS, SJS/TEN	Korean	2.06 (99.98)	(65)
		DRESS	Thai	8.26 (100)	(66)
		MPE, SJS/TEN	Japanese		(62, 67)
		MPE	Thai	5.13 (99.90)	(66)
		SJS/TEN	Caucasian		(14, 68)
			Thai	10.48 (100)	(66)
	C*03:02	DRESS, SJS/TEN	Korean	1.77 (99.98)	(65)
	A*33:02	DRESS, SJS/TEN	Korean	0.8 (99.96)	(65)
Carbimazole/ Methimazole	B*27:05	Agranulocytosis	European		(69)
	B*38:02		Han Chinese		(69)
	DRB1*08:03		Han Chinese		(69)
Fenofibrate	A*33:01	DILI	European		(70)
Flupirtine	DRB1*15:01	DILI	European		(71)
Isoxicam	A*02	SJS/TEN	Caucasian		(9)
	B*12				
Lapatinib	DRB1*07:01	DILI	Caucasian		(72)
			East Asian		
Lumiracoxib	DRB1*15:01	DILI	Caucasian	8 (98.9)	(73)
Methazolamide	B*59:01	SJS/TEN	Japanese		(74)
			Korean		(75)
			Han Chinese		100 (96.8)
Methimazole	C*03:02	DILI	Chinese		(77)
Oxicams	B*73	SJS/TEN	Caucasian		(14)
Penicillin	DRB1*10:01	Anaphylaxis	Caucasian		(78)
	B*55:01		European		(79)
Statins	DRB1*11:01	NAM	Pacific Islander		(80)
Strontium Renalate	A*33:03	SJS/TEN	Han Chinese		(81)
Sulfasalazine	B*13:01	DRESS	Han Chinese		(82)
Ticlopidine	A*33:03	DILI	Japanese		(83)
Ximelagatran	DRB1*07:01	DILI	European		(84)

- (1) Lucena, M.I. *et al.* Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. *Gastroenterology (New York, NY 1943)* **141**, 338-47 (2011).
- (2) Balas, A. *et al.* HLA-A* 68,-A* 11: 01, and-A* 29: 02 alleles are strongly associated with benzimidazole-induced maculopapular exanthema (MPE)/DRESS. *The Journal of Allergy and Clinical Immunology: In Practice*, (2020).
- (3) Zhang, F.-R. *et al.* HLA-B* 13: 01 and the dapsone hypersensitivity syndrome. *New England Journal of Medicine* **369**, 1620-8 (2013).
- (4) Tempark, T. *et al.* Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. *Pharmacogenet Genomics* **27**, 429-37 (2017).
- (5) Chen, W.T. *et al.* The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions. *The Journal of investigative dermatology* **138**, 1546-54 (2018).
- (6) Nicoletti, P. *et al.* Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. *Clinical Pharmacology & Therapeutics* **106**, 245-53 (2019).
- (7) Daly, A.K. *et al.* HLA-B5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nature genetics* **41**, 816-9 (2009).
- (8) Urban, T.J. *et al.* Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor. *Journal of Hepatology* **67**, 137-44 (2017).
- (9) Roujeau, J.C., Huynh, T.N., Bracq, C., Guillaume, J.C., Revuz, J. & Touraine, R. Genetic susceptibility to toxic epidermal necrolysis. *Arch Dermatol* **123**, 1171-3 (1987).
- (10) Özkaya-Bayazit, E. & Akar, U. Fixed drug eruption induced by trimethoprim-sulfamethoxazole: Evidence for a link to HLA-A30 B13 Cw6 haplotype. *Journal of the American Academy of Dermatology* **45**, 712-7 (2001).
- (11) Nakamura, R. *et al.* Association of HLA-A*11:01 with Sulfonamide-Related Severe Cutaneous Adverse Reactions in Japanese Patients. *Journal of Investigative Dermatology* **140**, 1659-62.e6 (2020).
- (12) Wang, C.-W. *et al.* Whole genome sequencing identifies genetic variants associated with cotrimoxazole hypersensitivity in Asians. *Journal of Allergy and Clinical Immunology*.
- (13) Li, Y.-J. *et al.* HLA-B14:01 and HLA-B35:01 are associated with trimethoprim-sulfamethoxazole induced liver injury. *Hepatology (Baltimore, Md)*, (2020).
- (14) Lonjou, C. *et al.* A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. *Pharmacogenetics and Genomics* **18**, 99-107 (2008).
- (15) Fontana, R.J. *et al.* The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. *Journal of Hepatology* **69**, 1317-25 (2018).
- (16) Konvinse, K.C. *et al.* HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. *J Allergy Clin Immunol* **144**, 183-92 (2019).
- (17) Li, L.-J., Hu, F.-Y., Wu, X.-T., An, D.-M., Yan, B. & Zhou, D. Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese. *Epilepsy research* **106**, 296-300 (2013).
- (18) Shi, Y.-W. *et al.* Association between HLA and Stevens–Johnson Syndrome Induced by Carbamazepine in Southern Han Chinese: Genetic Markers besides B*1502? *Basic & Clinical Pharmacology & Toxicology* **111**, 58-64 (2012).
- (19) Niihara, H., Kakamu, T., Fujita, Y., Kaneko, S. & Morita, E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. *The Journal of dermatology* **39**, 594-601 (2012).

- (20) Genin, E. *et al.* HLA-A* 31: 01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. *The pharmacogenomics journal* **14**, 281-8 (2014).
- (21) McCormack, M. *et al.* HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. *The New England journal of medicine* **364**, 1134-43 (2011).
- (22) Kim, S.-H. *et al.* Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. *Epilepsy research* **97**, 190-7 (2011).
- (23) Nicoletti, P. *et al.* Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. *Clinical pharmacology and therapeutics* **106**, 1028-36 (2019).
- (24) Tangamornsuksan, W., Chaiyakunapruk, N., Somkrua, R., Lohitnavy, M. & Tassaneeyakul, W. Relationship Between the HLA-B*1502 Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. *JAMA Dermatology* **149**, 1025-32 (2013).
- (25) Mehta, T.Y. *et al.* Association of HLA-B* 1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. *Indian Journal of Dermatology, Venereology, and Leprology* **75**, 579 (2009).
- (26) Sukasem, C. *et al.* Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients. *Journal of immunology research* **2018**, 1-11 (2018).
- (27) Chung, W.-H. *et al.* A marker for Stevens–Johnson syndrome. *Nature* **428**, 486- (2004).
- (28) Wang, Q., Sun, S., Xie, M., Zhao, K., Li, X. & Zhao, Z. Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: A meta-analysis. *Epilepsy research* **135**, 19-28 (2017).
- (29) Capule, F. *et al.* Association of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. *Pharmacogenomics J* **20**, 533-41 (2020).
- (30) Mockenhaupt, M. *et al.* HLA-B* 57: 01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. *Allergy* **74**, 2227-30 (2019).
- (31) Koomdee, N. *et al.* Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population. *Frontiers in pharmacology* **8**, 879- (2017).
- (32) Moon, J. *et al.* The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population. *Epilepsia* **56**, e161-7 (2015).
- (33) Kim, B.K. *et al.* HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population. *Ann Allergy Asthma Immunol* **118**, 629-30 (2017).
- (34) Kazeem, G.R. *et al.* High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. *Pharmacogenet Genomics* **19**, 661-5 (2009).
- (35) Cheung, Y.-K., Cheng, S.-H., Chan, E.J.M., Lo, S.V., Ng, M.H.L. & Kwan, P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. *Epilepsia* **54**, 1307-14 (2013).
- (36) Sabourirad, S. *et al.* Investigating the association of Lamotrigine and Phenytoin-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis with HLA-B*1502 in Iranian population. *Exp Dermatol*, (2020).
- (37) Zhao, T. *et al.* The Association Between HLA-A*03:01 and HLA-B*07:02 Alleles and Oxcarbazepine-induced Maculopapular Eruption in the Uighur Chinese Population. *Seizure* **81**, 43-6 (2020).
- (38) Hung, S.I. *et al.* Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. *Pharmacogenomics* **11**, 349-56 (2010).
- (39) Lv, Y.-D. *et al.* The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a Northern Han Chinese population. *BMC Neurology* **13**, 75 (2013).

- (40) Kaniwa, N. *et al.* Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. *Pharmacogenomics* **14**, 1821-31 (2013).
- (41) Su, S.C. *et al.* HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians. *Clinical pharmacology and therapeutics* **105**, 476-85 (2019).
- (42) Chang, C.C. *et al.* Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. *The Pharmacogenomics Journal* **17**, 170-3 (2017).
- (43) Locharernkul, C. *et al.* Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B* 1502 allele in Thai population. *Epilepsia* **49**, 2087-91 (2008).
- (44) Tassaneeyakul, W. *et al.* Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. *Pharmacogenetics and Genomics* **26**, 225-34 (2016).
- (45) Somogyi, A.A., Barratt, D.T., Phillips, E.J., Moore, K., Ilyas, F. & Gabb, G.M. High and variable population prevalence of HLA-B* 56: 02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms. *British journal of clinical pharmacology* **85**, 2163-9 (2019).
- (46) Hung, S.-I. *et al.* Common risk allele in aromatic antiepileptic-drug induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han Chinese. *Pharmacogenomics* **11**, 349-56 (2010).
- (47) Saag, M. *et al.* High sensitivity of human leukocyte antigen-b* 5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. *Clinical infectious diseases* **46**, 1111-8 (2008).
- (48) Mallal, S. *et al.* HLA-B* 5701 screening for hypersensitivity to abacavir. *New England Journal of Medicine* **358**, 568-79 (2008).
- (49) Mallal, S. *et al.* Association between presence of HLA-B* 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *The Lancet* **359**, 727-32 (2002).
- (50) Sousa-Pinto, B. *et al.* Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01. *J Allergy Clin Immunol* **136**, 1092-4.e3 (2015).
- (51) Gao, S., Gui, X.-e., Liang, K., Liu, Z., Hu, J. & Dong, B. HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients. *AIDS research and human retroviruses* **28**, 540-3 (2012).
- (52) Carr, D.F. *et al.* Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. *Clinical Infectious Diseases* **56**, 1330-9 (2013).
- (53) Carr, D.F. *et al.* Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. *Journal of Antimicrobial Chemotherapy* **72**, 1152-62 (2017).
- (54) Gatanaga, H. *et al.* HLA-Cw8 primarily associated with hypersensitivity to nevirapine. *AIDS* **21**, (2007).
- (55) Littera, R. *et al.* HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. *AIDS* **20**, (2006).
- (56) Chantarangsu, S. *et al.* HLA-B* 3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. *Pharmacogenetics and genomics* **19**, 139-46 (2009).
- (57) Martin, A.M. *et al.* Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. *AIDS (London, England)* **19**, 97-9 (2005).

- (58) Thomas, M. *et al.* Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir. *Clinical Infectious Diseases* **64**, 1198-203 (2017).
- (59) Her, Y., Kil, M.S., Park, J.H., Kim, C.W. & Kim, S.S. Stevens–Johnson syndrome induced by acetazolamide. *The Journal of Dermatology* **38**, 272-5 (2011).
- (60) Liu, Y. *et al.* Class II HLA Variants Associate with Risk of Pegaspargase Hypersensitivity. *Clinical pharmacology and therapeutics*, (2021).
- (61) Gagné, V. *et al.* Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients. *Pharmacogenomics* **20**, 1189-97 (2019).
- (62) Jarjour, S., Barrette, M., Normand, V., Rouleau, J.L., Dubé, M.P. & de Denus, S. Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review. *Pharmacogenomics* **16**, 755-67 (2015).
- (63) Gonçalo, M. *et al.* HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. *The British journal of dermatology* **169**, 660-5 (2013).
- (64) Chiu, M.L.S. *et al.* Association between HLA-B58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. *British journal of dermatology (1951)* **167**, 44-9 (2012).
- (65) Kang, H.-R. *et al.* Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. *Pharmacogenetics and genomics* **21**, 303-7 (2011).
- (66) Sukasem, C. *et al.* HLA-B (*) 58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand. *Frontiers in pharmacology* **7**, 186 (2016).
- (67) Kaniwa, N. *et al.* HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. *Pharmacogenomics* **9**, 1617-22 (2008).
- (68) Yu, K.H., Yu, C.Y. & Fang, Y.F. Diagnostic utility of HLA-B* 5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis. *International journal of rheumatic diseases* **20**, 1057-71 (2017).
- (69) Chen, W.-T. & Chi, C.-C. Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A systematic review and meta-analysis of pharmacogenomics studies. *British Journal of Clinical Pharmacology* **85**, 1878-87 (2019).
- (70) Nicoletti, P. *et al.* Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. *Gastroenterology* **152**, 1078-89 (2017).
- (71) Nicoletti, P. *et al.* HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. *Pharmacogenetics and genomics* **26**, 218-24 (2016).
- (72) Parham, L.R. *et al.* Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01. *The pharmacogenomics journal* **16**, 180-5 (2016).
- (73) Singer, J.B. *et al.* A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. *Nature Genetics* **42**, 711-4 (2010).
- (74) Nakatani, K. *et al.* Identification of HLA-A* 02: 06: 01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing. *Scientific reports* **9**, 1-8 (2019).
- (75) Tangamornsuksan, W. & Lohitnavy, M. Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. *The Pharmacogenomics Journal* **19**, 286-94 (2019).
- (76) Yang, F. *et al.* HLA-B*59:01: A marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. *The pharmacogenomics journal* **16**, (2015).

- (77) Li, X. *et al.* Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' disease patients. *Biomed Pharmacother* **117**, 109095 (2019).
- (78) Nicoletti, P. *et al.* Beta-lactam-induced immediate hypersensitivity reactions: A genome-wide association study of a deeply phenotyped cohort. *J Allergy Clin Immunol*, (2020).
- (79) Krebs, K. *et al.* Genome-wide Study Identifies Association between HLA-B(*)55:01 and Self-Reported Penicillin Allergy. *American journal of human genetics* **107**, 612-21 (2020).
- (80) Woolley, M., Stebbings, S. & Highton, J. Statin-associated immune-mediated necrotising myopathy: a New Zealand case series showing possible overrepresentation in Pacific Islanders. *Internal Medicine Journal* **48**, 32-6 (2018).
- (81) Lee, H.Y. *et al.* Increased risk of strontium ranelate-related SJS/TEN is associated with HLA. *Osteoporosis International* **27**, 2577-83 (2016).
- (82) Yang, F. *et al.* HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population. *Pharmacogenomics* **15**, 1461-9 (2014).
- (83) Hirata, K. *et al.* Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. *The Pharmacogenomics Journal* **8**, 29-33 (2008).
- (84) Kindmark, A. *et al.* Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. *The pharmacogenomics journal* **8**, 186-95 (2008).